Key facts
- This page summarizes Matthew Vincent Dolan's Form 4 filing for DEXCOM INC (DXCM).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 30 Jan 2025, 18:44.
Matthew Vincent Dolan - 28 Jan 2025 Form 4 Insider Report for DEXCOM INC (DXCM)
- Reporting relationship
- EVP, Strategy & Corporate Dev
- Issuer ticker
- DXCM
- Reported as of
- 28 Jan 2025
- Net transaction value
- -$102,820
- SEC form
- 4
- Accepted by SEC
- 30 Jan 2025, 18:44:26 UTC
- Prior SEC filing
- 16 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jereme M. Sylvain, as Attorney-in-Fact for Matthew Vincent Dolan
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Matthew Vincent Dolan filed Form 4 for DEXCOM INC (DXCM) on 30 Jan 2025.
Change
- Previous filing in this sequence was filed on 16 May 2024.
- Current net transaction value: -$102,820.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DXCM
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +3,048
- Change %
- +7.6%
- Price
- $0.000000
- Shares after
- 43,227
- Date
- 28 Jan 2025
- Ownership
- Direct
- Footnotes
- F1, F2
DXCM
transaction
Common Stock
Sale
- Transaction value
- $102,820
- Shares
- -1,183
- Change %
- -2.7%
- Price
- $86.91
- Shares after
- 42,044
- Date
- 29 Jan 2025
- Ownership
- Direct
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025.
Footnote F2
Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025, and 104 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on August 30, 2024.
Footnote F3
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.